HAL-MPE1 First-in-human

NCT02163018 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Peanut Allergy

Interventions

DRUG: HAL-MPE1
DRUG: Placebo

Sponsor

HAL Allergy